Works matching DE "ERLOTINIB"

Results: 1030

Expanding Options for Pancreatic Cancer... So Where Do We Go From Here?

Published in:

Oncology (08909091), 2014, v. 28, n. 1, p. 5

By:

KO, ANDREW H.

Publication type:

Article

The War on Pancreatic Cancer: We Are Not There Yet.

Published in:

2014

By:

VARADHACHARY, GAURI R.;
WOLFF, ROBERT A.

Publication type:

Opinion

Treatment of Metastatic Pancreatic Adenocarcinoma: A Review.

Published in:

Oncology (08909091), 2014, v. 28, n. 1, p. 70

By:

THOTA, RAMYA;
BERLIN, JORDAN D.;
PAUFF, JAMES M.

Publication type:

Article

Treatment of Metastatic Pancreatic Adenocarcinoma: New Options and Promising Strategies.

Published in:

2014

By:

LOWERY, MAEVE A.;
O'REILLY, EILEEN M.

Publication type:

Opinion

A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer.

Published in:

2019

By:

Nguyen, Cuc Thi Thu;
Petrelli, Fabio;
Scuri, Stefania;
Nguyen, Binh Thanh;
Grappasonni, Iolanda

Publication type:

journal article

Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non–small cell lung cancer (NSCLC) with brain metastases.

Published in:

European Journal of Clinical Pharmacology, 2020, v. 76, n. 10, p. 1427, doi. 10.1007/s00228-020-02926-9

By:

Shriyan, Bharati;
Patil, Deepali;
Gurjar, Murari;
Nookala, Manjunath;
Patil, Anand;
Kannan, Sadhana;
Patil, Vijay;
Joshi, Amit;
Noronha, Vanita;
Prabhash, Kumar;
Gota, Vikram

Publication type:

Article

Incidence of Adverse Cutaneous Reactions to Epidermal Growth Factor Receptor Inhibitors in Patients with Non-Small-Cell Lung Cancer.

Published in:

Dermatology (10188665), 2021, v. 237, n. 6, p. 929, doi. 10.1159/000513233

By:

Gisondi, Paolo;
Geat, Davide;
Mattiucci, Alessandra;
Lombardo, Fiorella;
Santo, Antonio;
Girolomoni, Giampiero

Publication type:

Article

Liquid Biopsy in EGFR -Mutated Advanced NSCLC from T790M to MET Amplification: Clinical Implications and Possibilities in the Resistance Setting.

Published in:

Journal of Molecular Pathology, 2023, v. 4, n. 2, p. 81, doi. 10.3390/jmp4020009

By:

Della Gravara, Luigi;
Battiloro, Ciro;
Avellino, Aniello;
Caputo, Francesca;
D'Aniello, Carmine;
Rocco, Danilo

Publication type:

Article

Erlotinib or Gefitinib for Treating Advanced Epidermal Growth Factor Receptor Mutation–Positive Lung Cancer in Aotearoa New Zealand: Protocol for a National Whole-of-Patient-Population Retrospective Cohort Study and Results of a Validation Substudy.

Published in:

JMIR Research Protocols, 2024, v. 13, p. 1, doi. 10.2196/51381

By:

Aye, Phyu Sin;
Barnes, Joanne;
Laking, George;
Cameron, Laird;
Anderson, Malcolm;
Luey, Brendan;
Delany, Stephen;
Harris, Dean;
McLaren, Blair;
Brenman, Elliott;
Wong, Jayden;
Lawrenson, Ross;
Arendse, Michael;
Tin Tin, Sandar;
Elwood, Mark;
Hope, Philip;
McKeage, Mark James

Publication type:

Article

LncRNA MALAT-1 modulates EGFR-TKI resistance in lung adenocarcinoma cells by downregulating miR-125.

Published in:

Discover Oncology, 2024, v. 15, n. 1, p. 1, doi. 10.1007/s12672-024-01133-7

By:

Luo, Jie;
Ren, Qiaoya;
Liu, Xiaoxi;
Zheng, Qian;
Yang, Ling;
Meng, Mi;
Ma, Hu;
He, Sisi

Publication type:

Article

FDA Announces Sagent Pharmaceuticals' Voluntary Nationwide Recall of Docetaxel Injection, USP.

Published in:: ONS Voice, 2024, p. 1
Publication type:: Article

FDA Announces Smiths Medical ASD Inc.'s Recall of Medfusion Model 3500 Syringe Pump.

Published in:: ONS Voice, 2024, p. 2
Publication type:: Article

FDA Approves Olaparib Plus Abiraterone and Prednisone or Prednisolone for BRCA-Variant, Metastatic, Castration- Resistant Prostate Cancer.

Published in:: ONS Voice, 2023, p. 1
Publication type:: Article

FDA Grants Accelerated Approval to Epcoritamab-Bysp for Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma.

Published in:: ONS Voice, 2023, p. 1
Publication type:: Article

Development and validation of HPLC method for simultaneous estimation of erlotinib and niclosamide from liposomes optimized by screening design.

Published in:

Journal of Liposome Research, 2023, v. 33, n. 3, p. 268, doi. 10.1080/08982104.2022.2162540

By:

Padakanti, Amruta Prabhakar;
Pawar, Sachin Dattaram;
Kumar, Pramod;
Chella, Naveen

Publication type:

Article

Development of asolectin-based liposomal formulation for controlled and targeted delivery of erlotinib as a model drug for EGFR monotherapy.

Published in:

Journal of Liposome Research, 2022, v. 32, n. 4, p. 386, doi. 10.1080/08982104.2022.2040532

By:

Pardeshi, Snehal;
Tiwari, Amrendra;
Titame, Uday;
Singh, Pankaj K;
Yadav, Pavan Kumar;
Chourasia, Manish K.

Publication type:

Article

Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.

Published in:

Basic & Clinical Pharmacology & Toxicology, 2017, v. 121, n. 4, p. 309, doi. 10.1111/bcpt.12801

By:

Parra‐Guillen, Zinnia P.;
Berger, Peter B.;
Haschke, Manuel;
Donzelli, Massimiliano;
Winogradova, Daria;
Pfister, Bogumila;
Früh, Martin;
Gillessen, Silke;
Krähenbühl, Stephan;
Kloft, Charlotte;
Joerger, Markus

Publication type:

Article

Potential Use of Hyperspectral Reflectance as a High-Throughput Nondestructive Phenotyping Tool for Assessing Salt Tolerance in Advanced Spring Wheat Lines under Field Conditions.

Published in:

Plants (2223-7747), 2021, v. 10, n. 11, p. 2512, doi. 10.3390/plants10112512

By:

El-Hendawy, Salah;
Al-Suhaibani, Nasser;
Mubushar, Muhammad;
Tahir, Muhammad Usman;
Refay, Yahya;
Tola, ElKamil

Publication type:

Article

Single‑agent nintedanib suppresses metastatic osteosarcoma growth by inhibiting tumor vascular formation.

Published in:

Oncology Letters, 2024, v. 27, n. 3, p. N.PAG, doi. 10.3892/ol.2024.14254

By:

Shimizu, Takatsune;
Sagara, Atsunobu;
Fukuchi, Yumi;
Muto, Akihiro

Publication type:

Article

A retrospective study of the efficacy of combined EGFR-TKI plus VEGF inhibitor/cytotoxic therapy vs. EGFR-TKI monotherapy for PD-L1-positive EGFR-mutant non-small cell lung cancer: North Japan Lung Cancer Study Group 2202.

Published in:

Oncology Letters, 2023, v. 26, n. 2, p. 1, doi. 10.3892/ol.2023.13920

By:

MINEHIKO INOMATA;
YOSUKE KAWASHIMA;
RYOTA SAITO;
DAISUKE MORINAGA;
HITOMI NOGAWA;
MASAMICHI SATO;
YOHEI SUZUK;
SATORU YANAGISAWA;
TAKASHI KIKUCHI;
DAISUKE JINGU;
NARUO YOSHIMURA;
TOSHIYUKI HARADA;
EISAKU MIYAUCHI

Publication type:

Article

Medicinal herbs and bioactive compounds overcome the drug resistance to epidermal growth factor receptor inhibitors in non-small cell lung cancer.

Published in:

Oncology Letters, 2021, v. 22, n. 3, p. N.PAG

By:

Lee, Hiu Yan Jennifer;
Meng, Mingjing;
Liu, Yulong;
Su, Tao;
Kwan, Hiu Yee

Publication type:

Article

Mechanism of intrinsic resistance of lung squamous cell carcinoma to epithelial growth factor receptor-tyrosine kinase inhibitors revealed by high-throughput RNA interference screening.

Published in:

Oncology Letters, 2020, v. 20, n. 6, p. N.PAG, doi. 10.3892/ol.2020.12218

By:

Ju, Lixia;
Dong, Zhiyi;
Yang, Juan;
Li, Minghua

Publication type:

Article

Effects of hyperinsulinemia on acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor via the PI3K/AKT pathway in non-small cell lung cancer cells in vitro.

Published in:

Oncology Letters, 2020, v. 20, n. 5, p. 1, doi. 10.3892/ol.2020.12069

By:

HSIN-YI CHIU;
CHI-MING CHIANG;
SZU-PENG YEH;
DE-SHIEN JONG;
LEANG-SHIN WU;
HUNG-CHANG LIU;
CHIH-HSIEN CHIU

Publication type:

Article

GLI1 activation is a key mechanism of erlotinib resistance in human non-small cell lung cancer.

Published in:

Oncology Letters, 2020, v. 20, n. 4, p. N.PAG

By:

Dong, Zhouhuan;
Wang, Yun;
Ding, Vivianne;
Yan, Xiang;
Lv, Yali;
Zhong, Mei;
Zhu, Fengwei;
Zhao, Po;
He, Charlotte;
Ding, Feng;
Shi, Huaiyin

Publication type:

Article

Implications of lipid droplets in lung cancer: Associations with drug resistance.

Published in:

Oncology Letters, 2020, v. 20, n. 3, p. 2091, doi. 10.3892/ol.2020.11769

By:

Jin, Chunlai;
Yuan, Peng

Publication type:

Article

Effect of erlotinib combined with cisplatin on IL-6 and IL-12 in mice with Lewis lung cancer.

Published in:

Oncology Letters, 2020, v. 20, n. 1, p. 902, doi. 10.3892/ol.2020.11632

By:

Zhang, Xu;
Chen, Jinliang;
Jin, Hongsong;
Zhao, Wei;
Chang, Zhibo;
Wu, Huijing

Publication type:

Article

A novel anti-EGFR monoclonal antibody (EMab-17) exerts antitumor activity against oral squamous cell carcinomas via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.

Published in:

Oncology Letters, 2020, v. 19, n. 4, p. 2809, doi. 10.3892/ol.2020.11384

By:

JUNKO TAKEI;
MIKA KATO KANEKO;
TOMOKAZU OHISHI;
MANABU KAWADA;
HIROYUKI HARADA;
YUKINARI KATO

Publication type:

Article

EGFR tyrosine kinase inhibitor therapy for lung cancer treatments and their clinical outcomes: A cohort study in Taiwan.

Published in:

Oncology Letters, 2019, v. 18, n. 6, p. 6090, doi. 10.3892/ol.2019.10942

By:

Chung, Ching-Hu

Publication type:

Article

Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines.

Published in:

Oncology Letters, 2019, v. 18, n. 3, p. 2977, doi. 10.3892/ol.2019.10643

By:

Wang, Hui-Li;
Liu, Yan-Chun;
Long, Ming-Peng;
Zheng, Chuan;
Yang, Jia-Hui

Publication type:

Article

Preliminary evaluation of the potential role of β‑elemene in reversing erlotinib‑resistant human NSCLC A549/ER cells.

Published in:

Oncology Letters, 2018, v. 16, n. 3, p. 3380, doi. 10.3892/ol.2018.8980

By:

Lin, Lan;
Li, Lianbin;
ChEN, Xiangqi;
ZENg, Bangwei;
Lin, Tingyan

Publication type:

Article

Gastrointestinal perforation during treatment with erlotinib plus bevacizumab in two patients with non-small cell lung cancer exhibiting epidermal growth factor receptor mutations: A case report.

Published in:

2018

By:

Yamaguchi, Teppei;
Gotoh, Yusuke;
Hattori, Hidekazu;
Katsuno, Hidetoshi;
Imaizumi, Kazuyoshi

Publication type:

Case Study

Antitumor activity of kinetochore-associated protein 2 siRNA against lung cancer patient-derived tumor xenografts.

Published in:

Oncology Letters, 2018, v. 15, n. 4, p. 4676, doi. 10.3892/ol.2018.7890

By:

Makita, Yukimasa;
Teratani, Mika;
Murata, Shumpei;
Hoashi, Yasutaka;
Matsumoto, Satoru;
Kawamata, Yuji

Publication type:

Article

Mitochondrial pathway-mediated apoptosis is associated with erlotinib-induced cytotoxicity in hepatic cells.

Published in:

Oncology Letters, 2018, v. 15, n. 1, p. 783, doi. 10.3892/ol.2017.7359

By:

Chen, Xueqin;
Yang, Shaoyu;
Pan, Yuelong;
Li, Xin;
Ma, Shenglin

Publication type:

Article

Evaluation of erlotinib for the treatment of patients with non-small cell lung cancer with epidermal growth factor receptor wild type.

Published in:

Oncology Letters, 2017, v. 14, n. 1, p. 306, doi. 10.3892/ol.2017.6118

By:

FUMIHIKO HIRAI;
MAKOTO EDAGAWA;
SHINICHIRO SHIMAMATSU;
RYO TOYOZAWA;
GOUJI TOYOKAWA;
KANAME NOSAKI;
MASAFUMI YAMAGUCHI;
TAKASHI SETO;
MITSUHIRO TAKENOYAMA;
YUKITO ICHINOSE

Publication type:

Article

Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations.

Published in:

Oncology Letters, 2017, v. 13, n. 6, p. 4433, doi. 10.3892/ol.2017.5980

By:

KRAWCZYK, PAWEL;
KOWALSKI, DARIUSZ M.;
RAMLAU, RODRYG;
KALINKA-WARZOCHA, EWA;
WINIARCZYK, KINGA;
STENCEL, KATARZYNA;
POWRÓZEK, TOMASZ;
RESZKA, KATARZYNA;
WOJAS-KRAWCZYK, KAMILA;
BRYL, MACIEJ;
WÓJCIK-SUPERCZYŃSKA, MAGDALENA;
GŁOGOWSKI, MACIEJ;
BARINOW-WOJEWÓDZKI, ALEKSANDER;
MILANOWSKI, JANUSZ;
KRZAKOWSKI, MACIEJ

Publication type:

Article

Comparative metabolomic analysis of HPAC cells following the acquisition of erlotinib resistance.

Published in:

Oncology Letters, 2017, v. 13, n. 5, p. 3437, doi. 10.3892/ol.2017.5940

By:

SOOYEUN LEE;
WON-JUN JANG;
BOYEON CHOI;
SANG HOON JOO;
CHUL-HO JEONG

Publication type:

Article

Acute myocardial infarction following erlotinib treatment for NSCLC: A case report.

Published in:

2016

By:

SHANSHAN DING;
FEI LONG;
SHUJUAN JIANG

Publication type:

Case Study

Prolonged complete response following gemcitabine-erlotinib combined therapy in advanced pancreatic cancer.

Published in:

2016

By:

CZARNECKA, ANNA M.;
KORZEŃ, PIOTR;
NOWAK-DEMENT, ANNA;
KUKWA, WOJCIECH;
KORNILUK, JAN;
SZCZYLIK1, CEZARY

Publication type:

Case Study

Eyelash trichomegaly following treatment with erlotinib in a non-small cell lung cancer patient: A case report and literature review.

Published in:

2015

By:

SHAN-BING WANG;
KAI-JIAN LEI;
JIA-PEI LIU;
YU-MING JIA

Publication type:

Case Study

Epidermal growth factor receptor mutation heterogeneity analysis of pulmonary sarcomatoid carcinoma successfully treated with erlotinib: A case report.

Published in:

2015

By:

FANGWEN ZOU;
GUIYUAN XIE;
JIN-AN MA;
DONG-AI ZHOU;
YI JIANG;
JIAO-YUN ZHENG

Publication type:

Case Study

Predictive factors in patients with EGFR mutation-negative non-small cell lung cancer treated with erlotinib.

Published in:

Oncology Letters, 2014, v. 8, n. 6, p. 2699, doi. 10.3892/ol.2014.2548

By:

HIDENOBU ISHII;
KOICHI AZUMA;
KAZUHIKO YAMADA;
TAKASHI KINOSHITA;
YOUHEI IMAMURA;
TOMOAKI HOSHINO

Publication type:

Article

A new receptor tyrosine kinase inhibitor, icotinib, for patients with lung adenocarcinoma cancer without indication for chemotherapy.

Published in:

Oncology Letters, 2014, v. 8, n. 4, p. 1563, doi. 10.3892/ol.2014.2386

By:

XIAO ZHENG;
GUAN LIU;
SHENGYE WANG;
YUNLI ZHANG;
WENLONG BAO;
DEHOU DENG;
WEIMING MAO;
MEIYU FANG

Publication type:

Article

Circulating free mitochondrial DNA concentration and its association with erlotinib treatment in patients with adenocarcinoma of the lung.

Published in:

Oncology Letters, 2014, v. 7, n. 6, p. 2180, doi. 10.3892/ol.2014.2006

By:

CHU-YUN HUANG;
YUH-MIN CHEN;
CHIEH-HUNG WU;
CHUN-MING TSAI;
YU-CHIN LEE;
REURY-PERNG PERNG;
JACQUELINE WHANG-PENG

Publication type:

Article

Erlotinib in a patient with vaginal carcinoma and pulmonary metastasis: A case report.

Published in:

2014

By:

QING MA;
YAO-YAO REN;
XIA LIU;
TING GONG;
DIAN-SHENG ZHONG

Publication type:

Case Study

The efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring driver mutations.

Published in:

Molecular & Clinical Oncology, 2019, v. 10, n. 6, p. 610

By:

Sakamoto, Hiroaki;
Tanaka, Hisashi;
Shiratori, Toshihiro;
Baba, Keisuke;
Ishioka, Yoshiko;
Itoga, Masamichi;
Taima, Kageaki;
Hasegawa, Yukihiro;
Takanashi, Shingo;
Tasaka, Sadatomo

Publication type:

Article

Atypical diffuse bilateral cystic lung changes secondary to erlotinib treatment in a patient with metastatic non-small cell lung carcinoma: A case report and literature review.

Published in:

2018

By:

Ansari, Jawaher;
Ali, Muhammad;
Bashir, Farhat;
Shaukat, Arif;
Farrag, Ashraf;
Ali, Arwa M.;
Batubara, Enas;
Farghaly, Hussein R.

Publication type:

Case Study

Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001).

Published in:

Molecular & Clinical Oncology, 2017, v. 6, n. 3, p. 409, doi. 10.3892/mco.2017.1154

By:

MASAYOSHI MIYAWAKI;
KATSUHIKO NAOKI;
SATOSHI YODA;
SOHEI NAKAYAMA;
RYOSUKE SATOMI;
TAKASHI SATO;
SHINNOSUKE IKEMURA;
KEIKO OHGINO;
KOTA ISHIOKA;
DAISUKE ARAI;
HO NAMKOONG;
KENGO OTSUKA;
MASAKI MIYAZAKI;
TETSUO TANI;
AOI KURODA;
MAKOTO NISHINO;
HIROYUKI YASUDA;
ICHIRO KAWADA;
HIDEFUMI KOH;
MORIO NAKAMURA

Publication type:

Article

Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors in patients with epidermal growth factor receptor gene mutation-positive lung cancer (Review).

Published in:

Molecular & Clinical Oncology, 2017, v. 6, n. 1, p. 3, doi. 10.3892/mco.2016.1099

By:

MASAYUKI TAKEDA;
KAZUHIKO NAKAGAWA

Publication type:

Article

Long-term disease stabilization following treatment with erlotinib in heavily pretreated patients with wild-type epidermal growth factor receptor non-small-cell lung carcinoma: Two case reports.

Published in:

2016

By:

SAKELLAKIS, MINAS;
KOUTRAS, ANGELOS;
PITTAKA, MARIA;
TSITSOPOULOS, EFSTATHIOS;
KALOFONOU, FOTINI;
KALOFONOS, HARALABOS P.

Publication type:

Case Study

Successful treatment of non‑small‑cell lung cancer with afatinib and a glucocorticoid following gefitinib‑ and erlotinib‑induced interstitial lung disease: A case report.

Published in:

Molecular & Clinical Oncology, 2016, v. 5, n. 4, p. 488, doi. 10.3892/mco.2016.981

By:

TETSUO TANI;
KATSUHIKO NAOKI;
TAKANORI ASAKURA;
TOSHIYUKI HIRANO;
SHOJI SUZUKI;
KEITA MASUZAWA;
HANAKO HASEGAWA;
AOI KURODA;
HIROYUKI YASUDA;
MAKOTO ISHII;
KENZO SOEJIMA;
TOMOKO BETSUYAKU

Publication type:

Article